| Combining traditional systemic and biologic therapies for psoriasis. | |
| | |
MedLine Citation:
|
PMID: 20430311 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The year 2010 marks 8 years since etanercept obtained approval from the Food and Drug Administration for the treatment of psoriatic arthritis. There are 6 biologic therapies approved by the Food and Drug Administration for the treatment of psoriasis and/or psoriatic arthritis. These biologics are often used in patients who have received, are receiving, or will receive in the future the traditional systemic antipsoriatics. In this article, the currently available data on combining these therapies are reviewed. |
| | |
Authors:
|
Michael P Heffernan |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Seminars in cutaneous medicine and surgery Volume: 29 ISSN: 1558-0768 ISO Abbreviation: Semin Cutan Med Surg Publication Date: 2010 Mar |
Date Detail:
|
Created Date: 2010-04-30 Completed Date: 2010-08-12 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9617260 Medline TA: Semin Cutan Med Surg Country: United States |
Other Details:
|
Languages: eng Pagination: 67-9 Citation Subset: IM |
Affiliation:
|
Clinical Dermatology, St. Louis, MO 63117, USA. heffernan@centralderm.com <heffernan@centralderm.com> |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anti-Inflammatory Agents
/
therapeutic use* Biological Products / therapeutic use* Combined Modality Therapy Dermatologic Agents / therapeutic use* Humans Immunologic Factors / therapeutic use* Phototherapy* Psoriasis / therapy* |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Inflammatory Agents; 0/Biological Products; 0/Dermatologic Agents; 0/Immunologic Factors |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The future of biological therapies.
Next Document: Headache.